Foghorn Therapeutics, Inc. (FHTX)

Over the past six months, Foghorn Therapeutics reported Q3 2025 EPS of -$0.25 and revenue of $8.15 million, both exceeding estimates. The company announced a $50 million equity financing in January 2026, expected to extend the cash runway into the first half of 2028. Several investment banks initiated or reiterated Buy ratings and price targets for FHTX. Jeff Sacher was appointed as interim CFO and treasurer in December 2025. As of November 2025, Foghorn Therapeutics had cash worth US$180 million and a cash runway of approximately 2.0 years. FHTX's share price has been volatile and underperformed the S&P500 Index by -12.23% over the past six months.

Foghorn Therapeutics' products and services are not subject to typical demand seasonality. The demand for its potential future products will be driven by medical need, regulatory approvals, and market adoption rather than seasonal fluctuations. The company's current focus is on research and development and clinical trials, which do not exhibit seasonal demand patterns.

Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target genetically determined dependencies within the chromatin regulatory system to treat serious diseases, primarily in oncology. The company utilizes its Gene Traffic Control platform to identify and validate potential drug targets. Foghorn's pipeline includes oncology product candidates such as FHD-286, a selective inhibitor of variant SWI/SNF chromatin remodeling complexes, and FHD-909 (LY4050784), a potent, selective, and orally available small molecule that inhibits the ATPase activity of SMARCA2. Additionally, Foghorn has preclinical programs for selective SMARCA2, CBP, and EP300 degraders, as well as an ARID1B degrader program.

Foghorn Therapeutics, Inc. primarily conducts its discovery, development, and research and development activities in the United States and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics is viewed as a clinical-stage biotechnology company focused on innovative epigenetic therapies for cancer. Analyst consensus ratings are largely positive, with a "Strong Buy" rating from 80% of analysts. The advancement of its lead candidates and successful equity financing contribute positively to its reputation. However, the company faces challenges due to uncertain regulatory timelines, competition, potential dilution, and current unprofitability. While FHTX exceeded the US market's return over the past year, it underperformed the US Biotechs industry.

The ownership structure of Foghorn Therapeutics stock includes institutional investors (57.97%), insiders (1.11%), and public companies and individual investors (40.92%). Major institutional owners include Flagship Pioneering Inc., Fmr Llc, and Bvf Inc/il. The CEO, Adrian H. Gottschalk, directly owns 0.87% of the company's shares.